smokenscott or smokensox or whoever you are: If
Post# of 72446
(Total Views: 485)
Posted On: 04/23/2019 9:44:14 PM
smokenscott or smokensox or whoever you are:
If we can’t say B-OM was a huge success is it Ok if we say:
Transformative
Successfully evaluated
Successfully completed Phase 2 trial
Large Unmet need and a substantial market opportunity
Fill that large therapeutic gap in cancer care and give patients preventative relief
Attractive to doctors and patients translating to rapid market adoption
Demonstrated a strong therapeutic benefit
Met its primary endpoint showing a reduction of Severe OM incidence versus placebo
Beneficial treatment effects in reducing the duration of Severe OM and in delaying the onset of Severe OM.
Regards,
DRANMOKELT
From 4/23/19 PR
“Our clinical testing of Brilacidin oral rinse in Head and Neck Cancer patients undergoing chemoradiation, to date, has shown that it markedly decreases the incidence of severe oral mucositis.
A potentially transformative treatment, Brilacidin, after years of largely ineffective treatment attempts by others, may be on the cusp of helping to solve this global unmet need in cancer care.”
From 2/19/19 PR
Brilacidin has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease and serious skin infections, with planned extension into dermatological diseases.
“Oral mucositis represents a large area of unmet need and a substantial market opportunity. We, along with potential Pharma partners, feel Brilacidin—as a conveniently-administered oral rinse—is well-positioned possibly to emerge one day as a frontline, go-to treatment for this common, costly and debilitating side-effect of chemoradiation.”
Because it cannot be predicted which patients will develop SOM, a preventative treatment, such as Brilacidin oral rinse, would begin in all patients as soon as starting chemoradiation and continue until its completion (typically a seven-week course). Given Brilacidin is administered as a convenient oral rinse, with plans to package it in an easily transportable sachet form, the Company believes it would be attractive both to doctors and patients—likely translating to widespread and rapid market adoption should Brilacidin oral rinse gain regulatory
From 1/8/19 PR
We are highly confident that Brilacidin oral rinse could fill that large therapeutic gap in cancer care and give patients preventative relief from a frequently occurring and horrible consequence of chemoradiation.”
Successfully completed Phase 2 trial, Brilacidin oral rinse significantly reduced the incidence of severe OM
From 10/24/18 PR
The Company’s Brilacidin oral rinse demonstrated a strong therapeutic benefit in patients receiving an aggressive chemotherapy regimen (cisplatin administered 80-100 mg/m2, every 21 days), which currently is the standard of care. In this patient population, the incidence of Severe OM was reduced to 25.0% in the modified Intent-to-Treat (mITT) population, versus 71.4% of patients on placebo. In the Per Protocol (PP) patient group, incidence of Severe OM dropped to 14.3% for patients receiving Brilacidin-OM, compared to 72.7% among those receiving placebo.
The completed Phase 2 study met its primary endpoint, showing a reduction of Severe OM incidence versus placebo, as well as beneficial treatment effects in reducing the duration of Severe OM and in delaying the onset of Severe OM.
If we can’t say B-OM was a huge success is it Ok if we say:
Transformative
Successfully evaluated
Successfully completed Phase 2 trial
Large Unmet need and a substantial market opportunity
Fill that large therapeutic gap in cancer care and give patients preventative relief
Attractive to doctors and patients translating to rapid market adoption
Demonstrated a strong therapeutic benefit
Met its primary endpoint showing a reduction of Severe OM incidence versus placebo
Beneficial treatment effects in reducing the duration of Severe OM and in delaying the onset of Severe OM.
Regards,
DRANMOKELT
From 4/23/19 PR
“Our clinical testing of Brilacidin oral rinse in Head and Neck Cancer patients undergoing chemoradiation, to date, has shown that it markedly decreases the incidence of severe oral mucositis.
A potentially transformative treatment, Brilacidin, after years of largely ineffective treatment attempts by others, may be on the cusp of helping to solve this global unmet need in cancer care.”
From 2/19/19 PR
Brilacidin has been successfully evaluated in clinical trials in oral mucositis, inflammatory bowel disease and serious skin infections, with planned extension into dermatological diseases.
“Oral mucositis represents a large area of unmet need and a substantial market opportunity. We, along with potential Pharma partners, feel Brilacidin—as a conveniently-administered oral rinse—is well-positioned possibly to emerge one day as a frontline, go-to treatment for this common, costly and debilitating side-effect of chemoradiation.”
Because it cannot be predicted which patients will develop SOM, a preventative treatment, such as Brilacidin oral rinse, would begin in all patients as soon as starting chemoradiation and continue until its completion (typically a seven-week course). Given Brilacidin is administered as a convenient oral rinse, with plans to package it in an easily transportable sachet form, the Company believes it would be attractive both to doctors and patients—likely translating to widespread and rapid market adoption should Brilacidin oral rinse gain regulatory
From 1/8/19 PR
We are highly confident that Brilacidin oral rinse could fill that large therapeutic gap in cancer care and give patients preventative relief from a frequently occurring and horrible consequence of chemoradiation.”
Successfully completed Phase 2 trial, Brilacidin oral rinse significantly reduced the incidence of severe OM
From 10/24/18 PR
The Company’s Brilacidin oral rinse demonstrated a strong therapeutic benefit in patients receiving an aggressive chemotherapy regimen (cisplatin administered 80-100 mg/m2, every 21 days), which currently is the standard of care. In this patient population, the incidence of Severe OM was reduced to 25.0% in the modified Intent-to-Treat (mITT) population, versus 71.4% of patients on placebo. In the Per Protocol (PP) patient group, incidence of Severe OM dropped to 14.3% for patients receiving Brilacidin-OM, compared to 72.7% among those receiving placebo.
The completed Phase 2 study met its primary endpoint, showing a reduction of Severe OM incidence versus placebo, as well as beneficial treatment effects in reducing the duration of Severe OM and in delaying the onset of Severe OM.
(9)
(0)